InvestorsHub Logo
Followers 0
Posts 84
Boards Moderated 0
Alias Born 07/20/2006

Re: Telephonics post# 3585

Wednesday, 04/11/2007 8:43:06 AM

Wednesday, April 11, 2007 8:43:06 AM

Post# of 4764
The recent disclosure of the results from the SWOG Pancreatic trial-in which Erby failed to meet survival endpoints has been misinterpreted IMHO by the press. This population was "patients with locally advanced unresectable or metastatic pancreatic cancer"

It will be extremely interesting to see the results of the following studdy, in which patients that had successful resections were used: Even though it was a phase II, I believe that some results are already in.

"Phase II Randomized Study of Adjuvant Therapy Comprising Bevacizumab Versus Cetuximab in Combination With Gemcitabine Hydrochloride, Capecitabine, and Radiotherapy in Patients With Completely Resected Carcinoma of the Pancreas"

NCI


ECOG-E2204
NCT00305877, CALGB-ECOG-E2204, NCCTG-ECOG-E2204, SWOG-ECOG-E2204

This was a "faceoff" of ERBY vs. Avastin - both arms having Gen. and radiation.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.